[1] Koukourakis, M.I., Tsolos, C. and Tuoloupidis, S. (2007) Radical Hypofractionated Accelerated Radiotherapy with Cytoprotection for Invasive Bladder Cancer. Urology, 69, 245-250.
http://dx.doi.org/10.1016/j.urology.2006.09.064
[2] Astrahan, M. (2008) Some Implications of Linear-Quadratic-Linear Radiation Dose-Response with Regard to Hypofractionation. Medical Physics, 35, 4161-4172.
http://dx.doi.org/10.1118/1.2969065
[3] Fowler, J.F. (2010) 21 Years of Biologically Effective Dose. British Journal of Radiology, 83, 554-568.
[4] National Cancer Institute. Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.
http://ctep.cancer.gov/protocolDevelopment/adverse effects.htm
[5] Emami, B., Lyman, J., Brown, A., et al. (1991) Tolerance of Normal Tissue to Therapeutic Irradiation. International Journal of Radiation Oncology*Biology*Physics, 21, 109-122.
http://dx.doi.org/10.1016/0360-3016(91)90171-Y
[6] Marks, L.B., Yorke, E.D., Jackson, A., et al. (2010) Use of Normal Tissue Complication Models in the Clinic. International Journal of Radiation Oncology*Biology*Physics, 76, S10-S19.
http://dx.doi.org/10.1016/j.ijrobp.2009.07.1754
[7] Timmeman, R.D. (2008) An Overview of Hypofractionation and Introduction to This Issue of Seminars in Radiation Oncology. Seminars in Radiation Oncology, 18, 215-222.
[8] Hamilton, J., Higgins, G. and Bernhard, E.J. (2009) Conventional Radiotherapy or Hypofractionation? A Study of Molecular Changes Resulting from Different Radiation Fraction Schemes. Cancer Biology & Therapy, 8, 774-776.
http://dx.doi.org/10.4161/cbt.8.9.8341
[9] Matsuo, Y., Chen, F., Hamaji, M., et al. (2014) Comparison of Long-Term Survival Outcomes between Stereotactic Body Radiotherapy and Sublobar Resection for Stage I Non-Small-Cell Lung Cancer in Patients at High Risk for Lobectomy: A Propensity Score Matching Analysis. European Journal of Cancer, 50, 2932-2938.
http://dx.doi.org/10.1016/j.ejca.2014.09.006
[10] Yamashita, H., Onishi, H., Murakami, N., et al. (2015) Survival Outcomes after Stereotactic Body Radiotherapy for 79 Japanese Patients with Hepatocellular Carcinoma. Journal of Radiation Research, 53, 561-567.
http://dx.doi.org/10.1093/jrr/rru130
[11] National Cancer Institute. Bladder Cancer Treatment (PDQ). 31 March 2015, Date Last Accessed.
http://www.cancer.gov/cancertopics/pdq/treatment/bladder/HealthProfessional
[12] Nag, S., Erickson, B., Thomadsen, B., Orton, C., Demanes, J.D. and Petereit, D. (2000) The American Brachytherapy Society Recommendations for High-Dose-Rate Brachytherapy for Carcinoma of the Cervix. International Journal of Radiation Oncology, Biology, Physics, 48, 201-211.
http://dx.doi.org/10.1016/S0360-3016(00)00497-1
[13] Sundar, S., Symonds, P. and Deehan, C. (2003) Tolerance of Pelvic Organs to Radiation Treatment for Carcinoma of Cervix. Clinical Oncology, 15, 240-247.
http://dx.doi.org/10.1016/S0936-6555(02)00455-7
[14] National Cancer Institute. Cervical Cancer Treatment (PDQ). 31 March 2015, Date Last Accessed.
http://www.cancer.gov/cancer_information/
[15] Viswanathan, A.N., Yorke, E.D., Marks, L.B., Eifel, P.J. and Shipley, W.U. (2010) Radiation Dose-Volume Effects of the Urinary Bladder. International Journal of Radiation Oncology, Biology, Physics, 76, S116-S122.
http://dx.doi.org/10.1016/j.ijrobp.2009.02.090
[16] Panteliadou, M., Giatromanolaki, A., Touloupidis, S., Destouni, E., Tsoutsou, P.G., Pantelis, P., et al. (2012) Treatment of Invasive Bladder Cancer with Conformal Hopofractionated Accelerated Radiotherapy and Amifostine (HypoARC). Urologic Oncology, 30, 813-820.
http://dx.doi.org/10.1016/j.urolonc.2010.09.001
[17] Mitin, T., Shipley, W.U., Efstathiuo, J.A., Heney, N.M., Kaufman, D.S., Lee, R.J. and Zietman, A.L. (2013) Trimodality Therapy for Bladder Conservation in Treatment of Invasive Bladder Cancer. Current Urology Reports, 14, 109-115.
http://dx.doi.org/10.1007/s11934-012-0301-x
[18] Ploussard, G., Doneshmand, S., Efstathiou, J., Herr, H.W., James, N.D., Rodel, C.M., et al. (2014) Critical Analysis of Bladder Sparing with Trimodal Therapy in Muscle-Invasive Bladder Cancer: A Systematic Review. European Urology, 66, 120-137.
http://dx.doi.org/10.1016/j.eururo.2014.02.038
[19] Smith, Z.L., Christodouleas, J.P., Keefe, S.M., Malkowicz, S.B. and Guzzo, T.J. (2013) Bladder Preservation in the Treatment of Muscle-Invasive Bladder Cancer (MIBC): A Review of the Literature and a Practical Approach to Therapy. BJU International, 112, 13-25.
http://dx.doi.org/10.1111/j.1464-410X.2012.11762.x
[20] Foroudi, F., Pham, D., Rolfo, A., Bressel, M., Tang, C.I., Tan, A., et al. (2014) The Outcome of a Multi-Centre Feasibility Study of Online Adaptive Radiotherapy for Muscle-Invasive Bladder Cancer TROG 10.01 BOLART. Radiotherapy and Oncology, 111, 306-320.
http://dx.doi.org/10.1016/j.radonc.2014.02.015
[21] Turgeon, G.A., Souhami, L., Cury, F.L., Faria, S.L., Duclos, M., Sturgeon, J. and Kassouf, W. (2014) Hypofractionated Intensity Modulated Radiation Therapy in Combined Modality Treatment for Bladder Preservation in Elderly Patients with Invasive Bladder Cancer. International Journal of Radiation Oncology, Biology, Physics, 88, 326-331.
http://dx.doi.org/10.1016/j.ijrobp.2013.11.005
[22] Lalondrelle, S., Huddart, R., Warren-Oseni, K., Hansen, V.N., McNair, H., Thomas, K., et al. (2011) Adaptive-Predictive Organ Localization Using Cone-Beam Computed Tomography for Improved Accuracy in External Beam Radiotherapy for Bladder Cancer. International Journal of Radiation Oncology, Biology, Physics, 79, 705-712.
http://dx.doi.org/10.1016/j.ijrobp.2009.12.003